Peptide GLP-1 receptor agonists: From injection to oral delivery strategies.

Biochem Pharmacol

Protein Engineering and Biopharmaceuticals Science, Hubei University of Technology, Wuhan 430068, China; School of Pharmaceutical Sciences and Institute of Materia Medica, Xinjiang University, Urumqi 830017, China. Electronic address:

Published: November 2024

Peptide glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective drugs for treating type 2 diabetes (T2DM) and have been proven to benefit the heart and kidney. Apart from oral semaglutide, which does not require injection, other peptide GLP-1RAs need to be subcutaneously administered. However, oral semaglutide also faces significant challenges, such as low bioavailability and frequent gastrointestinal discomfort. Thus, it is imperative that advanced oral strategies for peptide GLP-1RAs need to be explored. This review mainly compares the current advantages and disadvantages of various oral delivery strategies for peptide GLP-1RAs in the developmental stage and discusses the latest research progress of peptide GLP-1RAs, providing a useful guide for the development of new oral peptide GLP-1RA drugs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2024.116471DOI Listing

Publication Analysis

Top Keywords

peptide glp-1ras
16
strategies peptide
12
receptor agonists
8
oral delivery
8
delivery strategies
8
oral semaglutide
8
peptide
7
oral
6
glp-1ras
5
peptide glp-1
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!